MaaT Pharma Announces Poster Presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
27 September 2023 - 6:00PM
Business Wire
- Two posters selected for non-clinical data presentation at
leading immuno-oncology conference for the Company’s new drug
candidate generation, MaaT03X, in combination with Immune
Checkpoint Inhibitors (ICIs), for the first time.
Regulatory News:
MaaT Pharma (EURONEXT: MAAT – the “Company”), a
clinical-stage biotechnology company and a leader in the
development of Microbiome Ecosystem TherapiesTM (MET) dedicated to
enhancing survival for patients with cancer, announced today
that two abstracts have been accepted for poster presentations at
the 38th Society for Immunotherapy of Cancer (SITC) Annual Meeting,
the world-leading event in immunotherapy, scheduled to be held from
November 1-5, 2023, in San Diego, California, U.S.A. This is the
first time that the Company will present non-clinical data in
immuno-oncology which include its Artificial Intelligence (AI)
screening approach and in vitro results for the first member of the
new generation MaaT03X range of products dedicated to improving
responses in immunotherapy for patients with solid tumors.
Immune checkpoint inhibitor (ICI) therapies have become the
standard of care for treating solid tumors. However, only around
25% to 35% of patients respond to the treatment. Simultaneously,
numerous studies have indicated that immune homeostasis and the
diversity and richness of gut microbiota could improve the response
to ICI treatment1. This research opens promising new possibilities
for enhancing cancer treatment. The Company has chosen to pursue
this avenue, focusing on the potential of the gut microbiome's
diversity, richness, and its key functional networks, which could
be a game-changer in the field of immuno-oncology in the coming
years. In this context, the company has developed an AI-driven
program to select the most effective tailor-made microbiome for
specific indications in multiple areas, with a first focus on
ICI.
SITC Poster Presentations details:
Title: Evaluation of a new co-cultured microbiome ecosystem
therapy candidate (MaaT03X) for clinical testing as
adjuvant/neoadjuvant to immune checkpoint inhibitors in solid
tumors Abstract Number: 1321
Title: Robust Machine Learning (ML) approach for Screening
Microbiome Ecosystem Therapies (MET) Drug Candidates in combination
with Immune Checkpoint Inhibitors Abstract Number: 1304
In line with the embargo policy of the congress, additional
details on data scheduled to be presented at the 2023 edition of
SITC will be released on October 31st, 2023.
About MaaT Pharma
MaaT Pharma, a clinical-stage biotechnology company, has
established a complete approach to restoring patient-microbiome
symbiosis in oncology. Committed to treating cancer and
graft-versus-host disease (GvHD), a serious complication of
allogeneic stem cell transplantation, MaaT Pharma has launched, in
March 2022, an open-label, single-arm Phase 3 clinical trial in
patients with acute GvHD, following the achievement of its proof of
concept in a Phase 2 trial. Its powerful discovery and analysis
platform, gutPrint®, enables the identification of novel disease
targets, evaluation of drug candidates, and identification of
biomarkers for microbiome-related conditions. The company’s
Microbiome Ecosystem Therapies are produced through a standardized
cGMP manufacturing and quality control process to safely deliver
the full diversity of the microbiome in liquid and oral
formulations. MaaT Pharma benefits from the commitment of
world-leading scientists and established relationships with
regulators to support the integration of the use of microbiome
therapies in clinical practice. MaaT Pharma is listed on Euronext
Paris (ticker: MAAT).
Forward-looking Statements
All statements other than statements of historical fact included
in this press release about future events are subject to (i) change
without notice and (ii) factors beyond the Company’s control. These
statements may include, without limitation, any statements preceded
by, followed by or including words such as “target,” “believe,”
“expect,” “aim,” “intend,” “may,” “anticipate,” “estimate,” “plan,”
“project,” “will,” “can have,” “likely,” “should,” “would,” “could”
and other words and terms of similar meaning or the negative
thereof. Forward-looking statements are subject to inherent risks
and uncertainties beyond the Company’s control that could cause the
Company’s actual results or performance to be materially different
from the expected results or performance expressed or implied by
such forward-looking statements.
1 Routy B. et al, Science 2018, Matson et al, Science 2018,
Gopalakrishnan V. et al, Science, 2018
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230927694964/en/
MaaT Pharma – Investor Relations Guilhaume DEBROAS, Ph.D.
Head of Investor Relations +33 6 16 48 92 50 invest@maat-pharma.com
MaaT Pharma – Media Relations Pauline RICHAUD Senior PR
& Corporate Communications Manager +33 6 14 06 45 92
media@maat-pharma.com Trophic Communications – Corporate
Communications Charlotte SPITZ or Stephanie MAY +49 171 351
2733 maat@trophic.eu
Maat Pharma (EU:MAAT)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Maat Pharma (EU:MAAT)
Historical Stock Chart
Von Apr 2023 bis Apr 2024
